Publications by authors named "S Mimmi"
Article Synopsis
- Rituximab is a key chemotherapy drug for aggressive lymphomas like non-Hodgkin's lymphoma, often used in combination with chemotherapy (R-CHOP) as the first-line treatment.
- The study investigates IBTK's role in cancer progression, specifically its impact on the oncogene MYC in B-lymphomas.
- Findings suggest that silencing IBTK can enhance the anti-tumor effects of Rituximab, promoting cell death and potentially improving treatment outcomes for aggressive B-lymphomas.
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the lack of expression of estrogen and progesterone receptors and amplification of human epidermal growth factor receptor 2 (HER2). Being the Epidermal Growth Factor Receptor (EGFR) highly expressed in mesenchymal TNBC and correlated with aggressive growth behavior, it represents an ideal target for anticancer drugs. Here, we have applied the phage display for selecting two highly specific peptide ligands for targeting the EGFR overexpressed in MDA-MB-231 cells, a human TNBC cell line.
View Article and Find Full Text PDFObjectives: Nearly three years into the pandemic, SARS-CoV-2 infections are occurring in vaccinated and naturally infected populations. While humoral and cellular responses in COVID-19 are being characterized, novel immune biomarkers also being identified. Recently, an increase in angiotensin-converting enzyme 2 expressing (aka, ACE2 positive) circulating exosomes (ExoACE2) were identified in the plasma of COVID-19 patients (El-Shennawy et al.
View Article and Find Full Text PDF